The unavailability of medicines can be both problematic and lead to severe consequences for patients in need of therapy. However, in many cases other treatment alternatives can be provided. Quantify, in collaboration […]
At Quantify we are very proud of our research because of its positive impact on patients and the research community. Our CEO Kirk Geale proudly looks forward to our 2021 projects:
“We have such a great team at Quantify and I am continuously […]
Quantify’s Emma Söreskog, Ingrid Lindberg, Oskar Ström and Fredrik Borgström have co-authored two recently published papers on cost-effectiveness modelling in osteoporosis. One of the papers presents a […]
2020 has been a year of challenge and change for Quantify, the life science industry and society at large. We are heartened by the way people have come together to support one another, and this year we are especially proud […]
We hope that you did not miss our contribution to the multi-country CEA regarding COPD (Chronic Obstructive Pulmonary Disease) during ISPOR. Click here to see the full poster.
We are happy to announce that Quantify’s Trolle Jacobson and Thomas Fast has presented Q-PARK, one of our research platforms at ISPOR. With Q-PARK, it is possible to analyze switches and HCRU for patients with Parkinson´s disease. See the full […]
A new systematic literature review on patient quality of life in Alzheimer’s disease is now published. The study was co-authored by Anders Gustavsson and is part of the Innovative Medicines Initiative project […]
Quantify’s Ingrid, Mathias and Kirk are co-authors on an population-based Swedish RWE study of incidence of psoriaticarthritis in adults with skin psoriasis published in Acta D-V, and presented at AAD2020. The results showed that if 10,000 patients with skin psoriasis […]
QUANTIFY’s CEO Kirk Geale will be presenting an on-demand session titled “Nordic Decision-Making: Real-World Data and HTA” at the 2020 Canadian Agency for Drugs and Technologies in Health (CADTH) symposium, […]
Anders Gustavsson is co-author of a recently published Alzheimer study presenting a cross-walk between the generic health utility measure EQ5D and the disease specific health-related quality of life measure QoL-AD.
A free full text version is available here.